Pictet Asset Management
CRNX icon

Pictet Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Pictet Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.6M Buy
2,075,375
+191,094
+10% +$7.1M 0.07% 262
2026
Q1 		$68.2M Buy
1,884,281
+323,981
+21% +$14.5M 0.07% 265
2025
Q4 		$72.6M Buy
1,560,300
+95,038
+6% +$4.23M 0.07% 264
2025
Q3 		$61M Buy
1,465,262
+264,785
+22% +$8.47M 0.06% 285
2025
Q2 		$34.5M Buy
1,200,477
+153,462
+15% +$4.74M 0.04% 386
2025
Q1 		$35.1M Buy
1,047,015
+198,965
+23% +$7.43M 0.04% 373
2024
Q4 		$43.4M Sell
848,050
-60,099
-7% -$3.36M 0.05% 332
2024
Q3 		$46.4M Buy
908,149
+607,281
+202% +$31.3M 0.05% 304
2024
Q2 		$13.5M Buy
300,868
+291,501
+3,112% +$13.5M 0.02% 568
2024
Q1 		$438K Buy
9,367
+2,736
+41% +$107K ﹤0.01% 1358
2023
Q4 		$236K Buy
+6,631
New +$203K ﹤0.01% 1662

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
BSA
Braun Stacey Associates New York $3.53B AUM 63.32% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM

Pictet Asset Management's CRNX Position: Q2 2026 in Review

Pictet Asset Management increased its Crinetics Pharmaceuticals (CRNX) stake by 10% in Q2 2026, buying an estimated $7.1M and bringing the position to 2,075,375 shares worth $77.6M. The position accounts for 0.07% of the portfolio, ranked #262.

Pictet Asset Management first reported a position in CRNX in Q4 2023 and has held it in 11 quarters since. 100 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Pictet Asset Management held 2,075,375 shares of Crinetics Pharmaceuticals worth $77.6M as of Q2 2026.
  • Pictet Asset Management bought 191,094 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $7.1M.
  • Crinetics Pharmaceuticals made up 0.07% of Pictet Asset Management's portfolio in Q2 2026, its #262 holding.
  • Pictet Asset Management first reported a position in Crinetics Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 100 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.